MYGN — MYRIAD GENETICS INC
Price · 2024-08-26 → 2026-08-21
499 daily closes shownAnonymous view is capped at two years of history. A free account extends it to five, and Pro opens the whole archive back to 2016-01-04.
Performance
Technicals
Others in Healthcare
Measured signals that fired on MYGN
| date | signal | measured base rate |
|---|---|---|
| 2026-07-02 | Equal highs taken out structure | -0.70% over 21 days · t = -8.28 · n = 68,636 statistically distinguishable from its control group |
| 2026-05-18 | Equal lows taken out structure | -0.64% over 21 days · t = -4.75 · n = 55,661 statistically distinguishable from its control group |
Excess return against a matched control group, on a point-in-time universe that includes delisted companies. Most families do not survive that. How the measurement works →
Insider transactions (Form 4)
| date | insider | what | shares | price | value |
|---|---|---|---|---|---|
| 2026-08-16 | Wheeler Benjamin Richard Chief Financial Officer | Shares withheld for tax | 8.8K | 3.03 | 26.5K |
| 2026-06-11 | Donnelly Brian J Chief Commerical Officer | Grant or award | 5.0K | 3.94 | 19.7K |
| 2026-06-11 | Raha Samraat S. President and CEO | Grant or award | 3.5K | 3.94 | 13.9K |
| 2026-06-08 | Kumar Rashmi Director | Open-market sale 10b5-1 plan | 15.0K | 4.46 | 66.8K |
| 2026-06-04 | Davis Mark Steven Director | Grant or award | 59.7K | 0.00 | 0 |
| 2026-06-04 | Dreismann Heinrich Director | Grant or award | 59.7K | 0.00 | 0 |
| 2026-06-04 | Skovronsky Daniel Director | Grant or award | 59.7K | 0.00 | 0 |
| 2026-06-04 | Phanstiel S. Louise Director | Grant or award | 59.7K | 0.00 | 0 |
| 2026-06-04 | Kumar Rashmi Director | Grant or award | 59.7K | 0.00 | 0 |
| 2026-06-04 | Bisaro Paul Director | Grant or award | 59.7K | 0.00 | 0 |
Open-market purchases (code P) are the informative ones. Grants, option exercises and tax withholding are compensation mechanics, not decisions. How to read a Form 4 →
Largest institutional holders
| manager | value | shares |
|---|---|---|
| ORBIMED ADVISORS LLC | 122.9M | 125.0M |
| BlackRock, Inc. | 40.0M | 8.9M |
| MILLENNIUM MANAGEMENT LLC | 30.0M | 6.7M |
| GLENVIEW CAPITAL MANAGEMENT, LLC | 24.4M | 5.4M |
| D. E. Shaw & Co., Inc. | 20.2M | 4.5M |
| STATE STREET CORP | 19.9M | 4.4M |
| VANGUARD CAPITAL MANAGEMENT LLC | 17.7M | 3.9M |
| MORGAN STANLEY | 14.3M | 3.2M |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 11.6M | 2.6M |
| GOLDMAN SACHS GROUP INC | 10.6M | 2.4M |
13F positions as of 2026-03-31, filed up to 45 days after quarter end. Long-only US equity — shorts and derivatives never appear. What 13F does and does not show →
Latest SEC filings
| form | filed | period | |
|---|---|---|---|
| 4 | 2026-08-17 | 2026-08-16 | on EDGAR ↗ |
| SCHEDULE 13G/A | 2026-08-14 | — | on EDGAR ↗ |
| SCHEDULE 13G | 2026-08-14 | — | on EDGAR ↗ |
| SCHEDULE 13G | 2026-08-07 | — | on EDGAR ↗ |
| 10-Q | 2026-07-31 | 2026-06-30 | on EDGAR ↗ |
| 8-K | 2026-07-30 | 2026-07-30 | on EDGAR ↗ |
| 4 | 2026-06-23 | 2026-06-23 | on EDGAR ↗ |
| 8-K | 2026-06-23 | 2026-06-17 | on EDGAR ↗ |
Short selling
This is off-exchange short volume, not short interest: it is flow, not position, and 40–50% is normal because market makers short to fill your buy. Why that number misleads →
Recent headlines
- MYRIAD GENETICS INC (MYGN) filed form 4 · 2026-08-17 · SEC EDGAR
Ask the AI about MYGN
The assistant reads every block on this page — price history, filings, insider transactions, institutional positions, short volume, macro and the measured base rates — and says what it implies, quoting the number behind each claim and declaring what it does not have.
Everything on this page is live in the terminal.
Charts, filings, insider flow and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →